Back to Search
ANNE LIPTON, M.D.
M.D.
Neurology Physician
NPI: 1659434447Individual
Specialties, Licenses & Credentials
Neurology PhysicianPrimary
Psychiatry & Neurology — Neurology
Code: 2084N0400X
K9109(TX)
Research & Publications (20)
Subscores of the FAB differentiate frontotemporal lobar degeneration from AD.
PMID 16157906·Neurology·2005
8-other
Frontotemporal lobar degeneration with motor neuron disease-type inclusions predominates in 76 cases of frontotemporal degeneration.
PMID 15351890·Acta Neuropathol·2004
8-other
Lateralization on neuroimaging does not differentiate frontotemporal lobar degeneration from Alzheimer's disease.
PMID 15178946·Dement Geriatr Cogn Disord·2004
8-other
Differential activation on fMRI of monozygotic twins discordant for AD.
PMID 12771278·Neurology·2003
5-case
Contribution of asymmetric synapse loss to lateralizing clinical deficits in frontotemporal dementias.
PMID 11493163·Arch Neurol·2001
8-other
Effects of denosumab in patients with bone metastases with and without previous bisphosphonate exposure.
PMID 19653815·J Bone Miner Res·2010
3-trial
Elevated plasma endoglin (CD105) predicts decreased response and survival in a metastatic breast cancer trial of hormone therapy.
PMID 19115106·Breast Cancer Res Treat·2010
3-trial
Phase I trial of zoledronic acid + imatinib mesylate (Gleevec) in patients with bone metastases.
PMID 19652577·Am J Clin Oncol·2010
3-trial
Natural history of malignant bone disease in breast cancer and the use of cumulative mean functions to measure skeletal morbidity.
PMID 19660124·BMC Cancer·2009
2-rct
Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates.
PMID 19237632·J Clin Oncol·2009
3-trial
Magnesium silicate dissolution investigated by 29Si MAS, 1H-29Si CPMAS, 25Mg QCPMG, and 1H-25Mg CP QCPMG NMR.
PMID 19652836·Phys Chem Chem Phys·2009
8-other
Zoledronic acid and skeletal complications in patients with solid tumors and bone metastases: analysis of a national medical claims database.
PMID 18720527·Cancer·2008
8-other
RANKL inhibition in the treatment of bone metastases.
PMID 18685421·Curr Opin Support Palliat Care·2008
6-review
Serum HER-2/neu and relative resistance to trastuzumab-based therapy in patients with metastatic breast cancer.
PMID 18661530·Cancer·2008
4-observational
Extended efficacy and safety of denosumab in breast cancer patients with bone metastases not receiving prior bisphosphonate therapy.
PMID 18927312·Clin Cancer Res·2008
3-trial
Synergistic inhibition with a dual epidermal growth factor receptor/HER-2/neu tyrosine kinase inhibitor and a disintegrin and metalloprotease inhibitor.
PMID 18757423·Cancer Res·2008
7-preclinical
Advancing treatment for metastatic bone cancer: consensus recommendations from the Second Cambridge Conference.
PMID 18927277·Clin Cancer Res·2008
6-review
Bone markers and their prognostic value in metastatic bone disease: clinical evidence and future directions.
PMID 18579314·Cancer Treat Rev·2008
6-review
Residue ionization in LpxC directly observed by 67Zn NMR spectroscopy.
PMID 18761443·J Am Chem Soc·2008
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 7515 GREENVILLE AVE, SUITE 503
DALLAS, TX 75231 - Phone
- (214) 345-5765
Quick Facts
- NPI
- 1659434447
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile